Senate Bill 3432
116th Congress(2019-2020)
Securing America’s Medicine Cabinet Act of 2020
Introduced
Introduced
Introduced in Senate on Mar 10, 2020
Overview
Text
Introduced
Mar 10, 2020
Latest Action
Mar 10, 2020
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
3432
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Tennessee
Arkansas
New Jersey
South Carolina
No Senate votes have been held for this bill.
Summary

Securing America's Medicine Cabinet Act of 2020

This bill encourages the development and approval of advanced pharmaceutical manufacturing technologies and designates certain university research centers to assist in developing such technologies.

The Food and Drug Administration (FDA) must continue to evaluate and approve new drug manufacturing technologies included in an application for drug approval and expedite the development and implementation of such technologies. The FDA must designate such a technology as an advanced manufacturing technology if it is likely to (1) prevent or resolve a drug shortage, (2) maintain an adequate supply of critical medications for national emergencies, or (3) promote the adoption of innovative approaches to drug design and manufacturing.

The sponsor of such a designated technology must provide the FDA with certain related scientific evidence. After receiving this evidence, if the FDA validates the technology for a proposed use, then the sponsor may use the validated technology across multiple manufacturing product lines within the same use context without obtaining additional FDA validation.

The FDA must designate certain institutions of higher education as National Centers of Excellence in Advanced Pharmaceutical Manufacturing. Among other requirements, such centers must demonstrate the ability to provide federal agencies with technical assistance and to train a future workforce in such technologies.

Text (1)
March 10, 2020
Actions (2)
03/10/2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
03/10/2020
Introduced in Senate
Public Record
Created
Mar 11, 2020 4:42:10 AM
Updated
Jan 30, 2021 5:34:01 AM